article thumbnail

Informa Connect’s Compliance Congress for Specialty Products

Drug Channels

Up your compliance game at this important event serving the unique sector of Specialty Products, the 7th annual Virtual Compliance Congress for Specialty Products.

article thumbnail

Massive Bio Launches Industry’s First NASA-Style, Oncology Clinical Trial Command Center to Disrupt and Accelerate Trial Enrollment, Featuring 72-Hour Instant Enrollment from Time of Patient Identification

The Pharma Data

Akin to the NASA Deep Space Network, SYNERGY-AI OCTCC is a real time data and communication network between patients, sites, and pharmaceutical companies, with the Massive Bio AI-enabled engine orchestrating these stakeholders for successful operations. NEW YORK–( BUSINESS WIRE )– Massive Bio, Inc. , 75N91020C00016.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

United Therapeutics Corporation Reports Third Quarter 2020 Financial Results

The Pharma Data

We commenced launch activities for the Remunity Pump for Remodulin, including shipping training devices to specialty pharmacies and certain health care practitioners, and entering into agreements with specialty pharmacies to purchase Remunity Pumps and accessories and to pre-fill the Remunity cartridges exclusively with Remodulin.

FDA 40
article thumbnail

ERLEADA® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.

The Pharma Data

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA ® (apalutamide) in the United States. Both tablet strengths are available via prescription through existing specialty pharmacy networks. FDA approval for mCSPC in September 2019.To